FAQ — Quality Control¶

Field	Value
Document ID	RPL-FAQ-QC-001
Version	1.0
Publisher	RPL Peptide (Qingdao RPL Biotechnology Co., Ltd.)
URL	https://rplpeptides.com
Last Updated	July 2026

1. QC vs QA¶

Q1: What is the difference between Quality Control and Quality Assurance?¶

A: Quality Control (QC) is the operational testing arm — it performs analytical tests (HPLC, MS, KF, LAL) on raw materials, in-process samples, and finished products to verify that they meet established specifications. Quality Assurance (QA) is the broader system that designs, implements, and maintains the processes to prevent quality issues from occurring in the first place. QA manages SOPs, audits, deviations, CAPA, and batch release review. In short: QC detects defects in the product; QA prevents defects in the process. Both are essential for reliable peptide products.

Q2: What is in-process QC versus final QC release testing?¶

A: In-process QC testing occurs during manufacturing — for example, monitoring coupling efficiency during SPPS, checking crude peptide purity before purification, or testing intermediate rinses. These tests allow early detection and correction of issues. Final QC release testing is performed on the finished, lyophilized product before it is released to inventory. Final tests include HPLC purity, mass spectrometry identity confirmation, appearance inspection, water content by Karl Fischer, and (if applicable) endotoxin testing and assay. Both stages are documented and linked to the batch record.

Q3: What does "batch release" mean, and who authorizes it?¶

A: Batch release is the formal decision that a production batch meets all acceptance criteria and can be distributed to customers. The Quality Assurance team reviews the complete batch record — including in-process test results, final QC test data, any deviations or out-of-specification (OOS) events, and corrective actions taken — before signing off on the release. For research-grade products, release is typically authorized by the QA manager or qualified person. Only released batches receive a Certificate of Analysis (COA).

Q4: How does QC handle out-of-specification (OOS) results?¶

A: When a QC test result falls outside the defined acceptance criteria, an OOS investigation is initiated. First, the laboratory error is ruled out (Phase I investigation): the analyst is interviewed, calculations are checked, instrument function is verified, and the original sample preparation is reviewed. If lab error is confirmed, the test is repeated with corrective action. If lab error is excluded, a Phase II investigation into the manufacturing process is launched, potentially involving root cause analysis, batch disposition review, and CAPA. An OOS result does not automatically mean the batch is rejected — but it does require formal investigation.

2. Analytical Methods¶

Q5: What is analytical method validation, and why is it important?¶

A: Method validation is the documented process of demonstrating that an analytical method is suitable for its intended purpose. According to ICH Q2 guidelines, validation covers specificity, accuracy, precision (repeatability and intermediate precision), linearity, range, detection limit (LOD), quantitation limit (LOQ), and robustness. A validated method provides confidence that test results — such as the 98.5% HPLC purity reported on a COA — are accurate, reliable, and reproducible across different analysts, instruments, and days. Without validation, QC results are not defensible.

Q6: What is specificity in analytical method validation?¶

A: Specificity is the ability of an analytical method to measure the target analyte unequivocally in the presence of other components — impurities, degradation products, excipients, or solvent residues. For peptide HPLC methods, specificity is demonstrated by showing that the target peptide peak is well-resolved (resolution ≥ 1.5) from all known and unknown impurity peaks. Stress studies (exposure to heat, light, acid, base, oxidant) are conducted to generate degradation products and confirm that none co-elute with the main peak. Poor specificity leads to inaccurate purity reporting.

Q7: What is linearity, and how is it assessed in peptide QC?¶

A: Linearity is the ability of a method to produce test results that are directly proportional to the concentration of the analyte within a given range. For peptide assay methods, linearity is assessed by preparing 5–7 standard solutions covering 50% to 150% of the expected test concentration and plotting response (e.g., peak area at 214 nm) versus concentration. The correlation coefficient (R²) should be ≥ 0.999 for a linear method. The slope, y-intercept, and residual analysis are also evaluated. Good linearity ensures accurate quantification across the working concentration range.

Q8: What is the difference between precision and accuracy in method validation?¶

A: Precision measures how close repeated measurements are to each other (the scatter of results), expressed as relative standard deviation (%RSD). Repeatability (same analyst, same day, same equipment) and intermediate precision (different analysts, different days) are both assessed. Accuracy measures how close the measured value is to the true value, expressed as percent recovery. A method can be precise but inaccurate (e.g., consistently measuring 95% when the true purity is 98%) or accurate but imprecise (e.g., measuring 97%, 99%, and 98% on three runs). Both are required for a validated method.

Q9: What analytical methods are typically used in peptide QC testing?¶

A: The core analytical methods for peptide QC include: (1) Reverse-Phase HPLC (RP-HPLC) at 214 nm for purity determination and impurity profiling; (2) Mass Spectrometry (ESI-TOF or ESI-QTOF) for molecular weight confirmation and identity verification; (3) Karl Fischer (KF) Coulometric Titration for water content; (4) Amino Acid Analysis (AAA) for composition verification — especially for custom peptides; (5) LAL (Limulus Amebocyte Lysate) Test for endotoxin detection when required; (6) Appearance inspection (visual examination of the lyophilized cake and reconstituted solution); and (7) pH measurement of a 1% solution.

Q10: How is HPLC purity reported on a COA?¶

A: HPLC purity is reported as the area percent of the target peptide peak relative to the total integrated peak area in the chromatogram at 214 nm (the amide bond absorbance). The typical formula is: Purity (%) = (Area of main peak / Total area of all peaks) × 100. The COA should also specify the HPLC conditions used (column type, gradient program, mobile phase composition, flow rate, detection wavelength) so that the end user can reproduce the analysis. Related impurities — those above 0.1% area — are often reported individually as "specified impurities."

3. Quality Standards¶

Q11: What are the USP and ICH guidelines relevant to peptide quality control?¶

A: The United States Pharmacopeia (USP) provides monographs for peptide drug substances, including general chapters <1039> (Chemically Synthesized Peptides — Assay and Impurities) and <787> (Subvisible Particulate Matter). The International Council for Harmonisation (ICH) guidelines most relevant to peptide QC are ICH Q2(R2) (Analytical Method Validation), ICH Q6A (Specifications), and ICH Q1A(R2) (Stability Testing). These guidelines define expectations for method performance, specification setting, and stability study design. While not all are mandatory for research-grade products, following them demonstrates a commitment to quality.

Q12: How are specification limits (acceptance criteria) determined for a peptide product?¶

A: Specification limits are established based on the product's intended use, manufacturing capability, and stability data. For research-grade peptides, typical specifications include: HPLC purity NLT 98.0%, water content NMT 5.0%, mass spectrum confirming the target molecular weight (± 0.5 Da), and appearance as "white to off-white powder." For premium research-grade or GMP-grade products, tighter limits are applied — e.g., purity NLT 99.0% and water content NMT 3.0%. Limits are set with manufacturing process capability (Cpk analysis) and stability trends in mind, ensuring that the product reliably meets its specification throughout its shelf life.

Q13: What is the difference between research grade and GMP grade peptides from a QC perspective?¶

A: Research-grade peptides are tested to quality standards suitable for laboratory research — typically ≥95–98% purity with HPLC, MS identity, water content, and appearance testing. GMP-grade peptides require cGMP-compliant manufacturing, full traceability from raw materials through final release, stricter impurity control (including individual specified impurity limits), additional testing (residual solvents, heavy metals, endotoxin, bioburden, microbial limits), and regulatory documentation (master batch records, validated methods, stability data in the final packaging configuration). The QC scope is broader, deeper, and more tightly controlled for GMP-grade materials.

Q14: How can I verify the QC data on a Certificate of Analysis?¶

A: To verify COA data, first confirm that the testing methods used are appropriate and validated. Check that the reported values fall within the acceptance criteria for each parameter. For HPLC purity notes, check that the detection wavelength (typically 214 nm for peptides) is correct and that the chromatogram includes integration details. For MS identity, verify that the observed molecular weight matches the theoretical value within the stated tolerance. If re-testing in your own lab, use the same analytical conditions specified on the COA and include a reference standard for comparison. Any significant discrepancy should be reported to the supplier.

Document Revision History¶

Version	Date	Changes
1.0	July 2026	Initial release

rplpeptides.com